We are continuing our review of some of the speakers and content at the Convention on April 2, 2017 in no particular order of their appearance at the event.
One of the more technical, but also most hopeful, presentations at our 2016 convention came from Dr. Mark Rollo, who enlightened the audience to the latest developments concerning abortion pill reversal. Dr. Rollo described new protocols to help women reverse RU-486 chemical abortions, a technique which uses two drugs: mifepristone (AKA RU-486) and misoprostol. In many cases, Dr. Rollo said, if massive dosages of progesterone are given after the mifepristone, but before the misoprostol, it is possible for a mother to bear the baby to term with no ill effects.
He noted that 18-25% of abortions are performed with mifepristone each year. That amounts to about 200,000 to 300,000. It is usually administered to the mother to be followed two days later by the misoprostol, giving a 48 hour window for her to change her mind. The drug combination may be prescribed up to 63 days after the first day of the last menstrual period (LMP).
Dr. Rollo also discussed how the progesterone reversal works and the success rate in actual patients, with most administrations resulting in the birth of healthy babies. Of the calls to the AbortionPillReversal.com national hotline number between May 2012 and February 2016, about 43% of the women go on to receive progesterone to attempt reversal and the approximate success rate has been 55% overall. Women in 45 states and 13 countries have participated in the abortion pill reversal.
Abortion pill reversal is not without its challenges though. With the short window of opportunity, it can be difficult for women to be reached and decide to reverse the effects of the abortion pill. Some women, despite assurances, are concerned about birth defects. They also face pressures from abortion clinics and lack of emotional support from friends and family. TMany doctors' offices also lack necessary progesterone supplies, as they do not often keep injectable progesterone on hand while its shelf-life of 3 to 6 months compounds the difficulty.
Dr. Rollo noted finally that more work can and needs to be done to develop new and more effective and prompt protocols for the use of progesterone to save lives.
This nationwide hotline with more than 300 doctors across the country participating saves lives. Dr. Rollo encouraged pro-lifers to invite pro-life medical professionals—including doctors, nurse practitioners, physicians assistants, and midwives—to join the APR network.